Or Eisenberg, Chief Financial Officer at NeuroSense Therapeutics Ltd. (NRSN), bought 250,000 shares at $0.80 ($200K) on 2026-06-16, disclosed to the SEC on 2026-06-17.
CFO Or Eisenberg purchased $200,000 worth of shares at $0.80 per share, representing the largest purchase of his career. This significant insider buy in a micro-cap biotech suggests the executive sees value despite the company's negative forward P/E.
The transaction executed at $0.80 per share, setting a reference point for the current valuation.
The $200,000 purchase at $0.80 per share is the largest insider buy in the company's history, signaling strong conviction from the CFO.
The company trades at a negative forward P/E of -0.86, indicating current losses. Additionally, a beta of 1.54 suggests the stock is highly volatile relative to the market.
Clearly above the average filing.